GlassScriptPhysician profile
Darren Eugene Mullins
NPI 1134189814
$3,642.16
in general payments reported to CMS, 2019-2025
32 companies · $1,310 in 2025
The $1,310 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $38.59 · 2021: $110 · 2023: $1,745 · 2024: $182 · 2025: $1,310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,650 · Food and Beverage: $1,492 · Education: $94.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,650.00 |
| Food and Beverage | $1,491.72 |
| Education | $94.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $1,650.00 | 2023 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $286.58 | 2019-2025 | Tagrisso, Calquence |
| Beone Medicines USA, INC. | $140.62 | 2025 | Brukinsa |
| Janssen Biotech, INC. | $131.38 | 2019-2023 | Rybrevant |
| Novartis Pharmaceuticals Corporation | $125.84 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $121.83 | 2025 | |
| Merck Sharp & Dohme LLC | $119.11 | 2019-2025 | Keytruda, Keytruda Qlex |
| Genzyme Corporation | $100.71 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $82.73 | 2019-2025 | Opdivo, Opdualag |
| Jazz Pharmaceuticals INC. | $81.93 | 2024-2025 | |
| Daiichi Sankyo INC. | $75.37 | 2024-2025 | Enhertu, Datroway |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.14 | 2025 | |
| Genentech USA, INC. | $68.56 | 2019-2025 | Venclexta, Phesgo |
| Seagen INC. | $63.27 | 2019-2021 | |
| Pfizer INC. | $56.83 | 2020-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $54.43 | 2025 | Opdivo, Opdualag |
| Horizon Therapeutics Plc | $34.30 | 2019 | |
| Gilead Sciences, INC. | $33.72 | 2025 | Trodelvy |
| Rigel Pharmaceuticals, INC. | $33.11 | 2025 | Rezlidhia, Tavalisse, Gavreto |
| Regeneron Healthcare Solutions, INC. | $30.20 | 2024 | Libtayo |
| Mirati Therapeutics, INC. | $29.95 | 2024 | Krazati |
| Alexion Pharmaceuticals, INC. | $29.32 | 2019-2025 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $28.91 | 2025 | Fruzaqla |
| Agios Pharmaceuticals, INC. | $28.47 | 2019 | |
| Incyte Corporation | $25.84 | 2025 | Jakafi |
| Sumitomo Pharma America, INC. | $25.12 | 2025 | Orgovyx |
| Taiho Oncology, INC. | $22.50 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $20.99 | 2021 | |
| Astellas Pharma US INC | $17.63 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $16.17 | 2025 | Somatuline Depot, Onivyde |
| W. L. Gore & Associates, INC. | $15.90 | 2025 | Gore Propaten Vascular Graft |
| Exelixis INC. | $15.70 | 2024 | Cabometyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darren Mullins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.